Latest news with #AneekaChatterjee
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
Liquor market: Microbreweries get a fresh fund pour to scale up biz
A microbrewery is a small-scale brewery that produces limited quantities of beer, typically upto 10 hecta litres per batch Aneeka Chatterjee Bengaluru Listen to This Article Microbreweries like Bengaluru-based Toit, Pune-based Big Little Brew Pub, and Hyderabad-based RedRhino Craft Brewery are raising fresh funding to expand and scale up operations amid the growing popularity of craft beers. A microbrewery is a small-scale brewery that produces limited quantities of beer, typically upto 10 hecta litres per batch. These entities are doubling down on growth as they look to strengthen their footprint, either by entering new territories or opening more outlets within India's beer capital, Bengaluru. Ironhill, for instance, is looking to raise ₹30 crore, which includes funds for a commercial brewing plant for kegging (the process of
&w=3840&q=100)
Business Standard
22-05-2025
- Business
- Business Standard
Century to unlock ₹14,000 cr GDV with ₹1,850 cr boost from investors
The funding, led by Ares Asia and SC Lowy, will support both ongoing and upcoming projects in the city across residential and commercial verticals Aneeka Chatterjee Bengaluru Listen to This Article Bengaluru-headquartered Century Real Estate aims to unlock ₹14,000 crore in Gross Development Value (GDV) over the next five years, following the successful securing of ₹1,850 crore in debt funding. The funding, led by Ares Asia and SC Lowy, will support both ongoing and upcoming projects in the city across residential and commercial verticals. The funding round, led by Ares Asia, brought in approximately ₹1,600 crore in two tranches, with SC Lowy contributing ₹250 crore. Speaking on the funds raised, Ravindra Pai, managing director, Century Real Estate, said: 'Securing the fund is a testament to the trust our financial partners place
&w=3840&q=100)
Business Standard
19-05-2025
- Business
- Business Standard
5 launches ahead; leading the GLP-1 market: Biocon Biologics MD & CEO
Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe Anjali Singh Aneeka Chatterjee Listen to This Article Biocon Biologics (BBL) reported robust growth in 2024-25 (FY25), driven by rising biosimilar market share in the US and emerging markets (EMs). Its Managing Director and Chief Executive Officer Shreehas P Tambe, in conversation with Anjali Singh and Aneeka Chatterjee, outlines the company's product pipeline, insulin strategy, glucagon-like peptide-1 (GLP-1) plans, and efforts to strengthen global presence. Edited excerpts: What were the key drivers for BBL's growth in the fourth quarter of FY25? Achieving 15 per cent year-on-year revenue growth, with nearly four biosimilars generating $200 million in revenue, is a huge feat. It reflects strong customer confidence in our
